Longeveron, Inc. (LGVN)
2.435
-0.04
(-1.81%)
USD |
NASDAQ |
Oct 12, 16:00
2.435
0.00 (0.00%)
After-Hours: 19:51
Longeveron EPS Diluted (Quarterly) : -1.936 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.936 |
| March 31, 2026 | -1.911 |
| December 31, 2025 | -2.374 |
| September 30, 2025 | -3.930 |
| June 30, 2025 | -3.349 |
| March 31, 2025 | -3.352 |
| December 31, 2024 | -2.740 |
| September 30, 2024 | -3.352 |
| June 30, 2024 | -18.30 |
| March 31, 2024 | -16.14 |
| December 31, 2023 | -25.52 |
| September 30, 2023 | -27.88 |
| June 30, 2023 | -26.68 |
| Date | Value |
|---|---|
| March 31, 2023 | -22.09 |
| December 31, 2022 | -21.20 |
| September 30, 2022 | -24.97 |
| June 30, 2022 | -26.85 |
| March 31, 2022 | -16.78 |
| December 31, 2021 | -19.49 |
| September 30, 2021 | -25.39 |
| June 30, 2021 | -26.21 |
| March 31, 2021 | -16.39 |
| December 31, 2020 | -7.153 |
| September 30, 2020 | -5.014 |
| December 31, 2019 | -2.479 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.073M |
| Revenue (Quarterly) | 0.287M |
| Total Expenses (Quarterly) | 6.36M |
| Enterprise Value | -1.630M |
| Gross Profit Margin (Quarterly) | -13.59% |
| Profit Margin (Quarterly) | -2.12K% |
| Earnings Yield | -416.9% |
| Normalized Earnings Yield | -416.86 |